MINUTENCT06031233
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 8 words
- Enrollment increased: 776 → 1082 participants
- Interventions modified
- Trial arms changed: 8 → 11
Notable Primary completion date: Jul 2026 to Jul 2028v4 Show 4 more changesShow less
- Enrollment target: 679 to 776
- Study completion date: Dec 2026 to Dec 2028
- Interventions: Atezolizumab (Drug), Bevacizumab (Drug), Durvalumab (Drug), Ipilimumab (Drug), Nivolumab (Drug), Pembrolizumab (Drug), Trastuzumab (Drug) to Atezolizumab (Drug), Bevacizumab (Drug), Durvalumab (Drug), Ipilimumab (Drug), Nivolumab (Drug), Pembrolizumab (Drug), Rituximab (Drug)…
- Study arms: 7 to 8
- Notable Primary completion date: Jul 2024 to Jul 2026
- Study completion date: Dec 2024 to Dec 2026
- Notable Trial status: Not Yet Recruiting to Recruitingv2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (1)
Arms and interventions
If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.
If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.
If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.
If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.
If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.
If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.
If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.
If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 15 minutes in the following cycles.
If no infusion reaction has occurred after 6 cycles, infusion time will stepwise be shortened to 10 minutes in the following cycles.
If no infusion reaction has occurred after 2 cycles, infusion time will stepwise be shortened to 1 minutes in the following cycles.
If no infusion reaction has occurred after 2 cycles, infusion time will stepwise be shortened to 10 minutes in the following cycles.
Drugs: Nivolumab, Pembrolizumab, Ipilimumab, Durvalumab, Atezolizumab, Bevacizumab, Trastuzumab, Rituximab, Infliximab, Vedolizumab, Tociliuzumab
Sites
1 site in 1 country
- Isala HospitalZwolle, Netherlands